Provided by Tiger Trade Technology Pte. Ltd.

Pfizer

28.00
+0.50001.82%
Post-market: 27.98-0.0164-0.06%19:57 EDT
Volume:31.23M
Turnover:874.14M
Market Cap:159.20B
PE:36.85
High:28.17
Open:27.62
Low:27.55
Close:27.50
52wk High:29.21
52wk Low:23.62
Shares:5.69B
Float Shares:5.64B
Volume Ratio:1.00
T/O Rate:0.55%
Dividend:1.72
Dividend Rate:6.14%
EPS(TTM):0.7599
EPS(LYR):1.36
ROE:5.01%
ROA:5.78%
PB:1.87
PE(LYR):20.52

Loading ...

From Lilly Deal to Market Darling: Inside Ginkgo's 120% Monthly Run

Bellwether Stocks Movement
·
Oct 06

NYSE Most Active Issues

Dow Jones
·
Oct 06

Analysts Conflicted on These Healthcare Names: Pfizer (PFE) and Genmab (GMAB)

TIPRANKS
·
Oct 05

One Molecule, Three Diseases, $1.55 Billion — Inside CSL's Bet

Bellwether Stocks Movement
·
Oct 05

Merck Doubled Off Its Lows — And Analysts Still See More Room

Bellwether Stocks Movement
·
Oct 05

CSL Bets $1.6 Billion on a Drug That Hasn't Finished Phase 2

Bellwether Stocks Movement
·
Oct 05

Pfizer (PFE) Quietly Builds New Cancer And RSV Powerhouse

TIPRANKS
·
Oct 03

Bayer Bets $2.2 Billion That America Is Still The Best Place To Make Drugs

Macro World​
·
Oct 03

23.3% Vs 14.8%: Lilly's New Data Just Changed The Obesity Drug Playbook

Bellwether Stocks Movement
·
Oct 03

Pfizer (PFE) Receives a Hold from Leerink Partners

TIPRANKS
·
Oct 03

NYSE Most Active Issues

Dow Jones
·
Oct 03

Pfizer Says Litfulo Safety Profile in NSV Consistent with Alopecia Areata

Reuters
·
Oct 03

Pfizer Tilrekimig Data Support TSLP Role in Atopic Dermatitis, UBS Says

MT Newswires Live
·
Oct 03

Pfizer’s TACTIVE-U Breast Cancer Combo Trial Reaches Key Milestone

TIPRANKS
·
Oct 03

Pfizer Says Phase 3 Trials Show Litfulo Improves Repigmentation in Nonsegmental Vitiligo Patients at Week 52

Reuters
·
Oct 02

Pfizer - to Submit Litfulo Phase 3 Data to FDA and Ema

THOMSON REUTERS
·
Oct 02

Pfizer - Litfulo Safety Profile in Nsv Consistent with Alopecia Areata; no New Safety Signals

THOMSON REUTERS
·
Oct 02

Pfizer’s Litfulo Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo~

THOMSON REUTERS
·
Oct 02

Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Tilray (TLRY)

TIPRANKS
·
Oct 02

Jefferies Adjusts Price Target on Pfizer to $35 From $34, Keeps Buy Rating

MT Newswires Live
·
Oct 02